Leukemia Clinical Trial
Official title:
Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial (AML-19) of the EORTC-LG and GIMEMA-ALWP
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and
either kill them or deliver cancer-killing substances to them without harming normal cells.
It is not yet known whether gemtuzumab ozogamicin is more effective than standard supportive
care in treating older patients who have acute myeloid leukemia.
PURPOSE: This randomized phase II/III trial is studying two different gemtuzumab ozogamicin
regimens to see how well they work compared to standard supportive care in treating older
patients with previously untreated acute myeloid leukemia.
OBJECTIVES:
- Compare the feasibility, toxicity, and antileukemic activity of two different dosing
regimens of gemtuzumab ozogamicin (GO) vs standard supportive care in older patients
with previously untreated acute myeloid leukemia who are not candidates for intensive
chemotherapy. (phase II)
- Compare the efficacy and toxicity of the best dosing regimen of GO selected from phase
II vs standard supportive care, in terms of overall survival, in these patients. (phase
III)
OUTLINE: This is a randomized, open-label, multicenter phase II study followed by a phase
III study. Patients are stratified according to age (61 to 75 vs 76 to 80 vs 81 and over),
CD33-positivity of bone marrow blasts (< 20% vs 20-80% vs > 80% vs unknown), initial WBC
before hydroxyurea administration (< 30,000/mm^3 vs ≥ 30,000/mm^3), WHO performance status
(0-1 vs 2 vs 3-4), and participating center.
- Phase II: Patients are randomized to 1 of 3 treatment arms.
- Arm I: Patients receive gemtuzumab ozogamicin (GO) IV over 2 hours on days 1 and
8. Patients with stable or responding disease at day 36 receive GO IV over 2 hours
every 4 weeks for up to 8 courses in the absence of disease progression or
unacceptable toxicity.
- Arm II: Patients receive GO IV over 2 hours on days 1, 3, and 5. Patients with
stable or responding disease at day 36 receive GO IV over 2 hours every 4 weeks
for up to 8 courses in the absence of disease progression or unacceptable
toxicity.
- Arm III: Patients receive standard supportive care.
- Phase III: Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive the selected treatment (arm I or arm II) from phase II.
- Arm II: Patients receive standard supportive care. Patients who receive GO
treatment are followed monthly for 1 year and then every 3 months thereafter.
Patients who receive standard supportive care are followed at least every 4 weeks.
PROJECTED ACCRUAL: A total of 259 patients (75 for phase II [25 per treatment arm] and 184
for phase III [92 per treatment arm]) will be accrued for this study within 2.5 years.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |